<DOC>
	<DOCNO>NCT00003733</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness sequential chemotherapy treat patient residual disease follow surgery stage IIB , stage III , stage IV ovarian cancer .</brief_summary>
	<brief_title>Sequential Chemotherapy Treating Patients With Residual Disease Following Surgery Stage IIB , Stage III , Stage IV Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy sequential carboplatin , paclitaxel , topotecan term disease response , time progression , survival progression free survival patient stage IIB , stage III , stage IV ovarian epithelial cancer . II . Assess toxicity regimen patient population . OUTLINE : Patients receive carboplatin IV 30 60 minute day 1 22 . Patients receive paclitaxel IV 3 hour day 43 64 , topotecan IV 30 minute daily 5 day begin day 85 , 106 , 127 , 148 . Treatment continue absence disease progression unacceptable toxicity . Patients follow monthly 3 month every 3 month 2 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced ovarian epithelial carcinoma great 1 cm residual disease completion initial surgery Stage IIB , IIIA , IIIB , IIIC , IV Measurable disease OR CA 125 great 120 units/mL obtain post surgery PATIENT CHARACTERISTICS : See General Eligibility Criteria PRIOR CONCURRENT THERAPY : Biological therapy : No prior concurrent immunotherapy Chemotherapy : No prior concurrent chemotherapy Endocrine : No prior concurrent hormonal therapy Radiotherapy : No prior radiotherapy No concurrent radiotherapy except limited field ( e.g. , palliation bone pain ) Surgery : Diagnostic surgery perform less 12 week prior study No concurrent interval debulking Other : At least 30 day five halflives since prior investigational therapy No concurrent investigational therapy Patients Characteristics Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Hemoglobin least 9.0 g/dL WBC least 4,000/mm3 Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGOT and/or SGPT great 2.5 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Alkaline phosphatase great 2.5 time ULN ( great 5 time ULN liver and/or bone metastases present ) Renal : Creatine le 2 time ULN Creatinine clearance least 50 mL/min Other : No prior malignancy except basal cell skin carcinoma carcinoma situ cervix No uncontrolled infection No concurrent medical condition would prevent full compliance expose patient extreme risk decrease life expectancy No concurrent medical condition treament platinum compound contraindicate No history allergy compound related drug use study No prior motor sensory neurotoxicity grade 2 bad Not pregnant nursing Fertile patient must use effective contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>